Sign up
Pharma Capital

Majority of NetScientific portfolio now at early commercial stage

Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), tells Proactive's Andrew Scott they're starting 2018 in a very strong position.

''Out of our five companies, three of them are at an early commercial stage''.

As far the broader strategic plan for 2018, he says the main focus is to continue helping the current portfolio to mature

'We're also looking at having new investors and the sector is also looking for consolidation .. so M&A is also part of our plans ''.

 

View full NSCI profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.